Can a patient taking apixaban (Eliquis) safely use a PPI?
Yes, a patient taking apixaban can safely use a proton pump inhibitor (PPI), and no dose adjustment of apixaban is required.
Key Evidence from FDA Labeling and Guidelines
The FDA prescribing information for Eliquis does not list PPIs as requiring dose adjustment or avoidance 1. Apixaban is a substrate of both CYP3A4 and P-glycoprotein (P-gp), but PPIs do not significantly inhibit or induce these pathways 1. This is fundamentally different from drugs like ketoconazole or ritonavax that are combined P-gp and strong CYP3A4 inhibitors, which do require apixaban dose reduction 1.
The 2024 ACC/AHA atrial fibrillation guidelines confirm that apixaban is metabolized minimally by CYP3A4 and is a P-gp substrate, but they do not identify PPIs as clinically significant interacting drugs 2. The 2022 drug interaction review explicitly states that clarithromycin (a combined P-gp and strong CYP3A4 inhibitor) does not require dose adjustment with apixaban, suggesting that even stronger inhibitors than PPIs pose minimal concern 3.
Clinical Evidence Supporting Safety
Multiple large-scale studies demonstrate that PPI co-therapy with apixaban is both safe and potentially beneficial:
A nationwide Korean cohort study showed that PPI co-therapy reduced upper GI bleeding hospitalization risk by 17.5% (weighted HR 0.825) in patients on oral anticoagulants 4
A Medicare study of 1.6 million patients found that apixaban users receiving PPI co-therapy had 34% lower risk of upper GI bleeding (IRR 0.66,95% CI 0.52-0.85) compared to those without PPIs 5
A pilot pharmacokinetic study directly measured anti-Xa activity in apixaban-treated patients and found no significant differences in trough or peak anti-Xa levels between PPI users and non-users 6
Practical Prescribing Approach
No dose adjustment is needed when prescribing PPIs with apixaban. The standard apixaban dosing remains:
- 5 mg twice daily (or 2.5 mg twice daily if patient meets ≥2 of: age ≥80 years, weight ≤60 kg, serum creatinine ≥1.5 mg/dL) 2, 1
Consider PPI co-therapy in apixaban patients with:
- Age >65 years
- History of peptic ulcer disease or prior GI bleeding
- Concurrent antiplatelet therapy (aspirin, clopidogrel)
- Concurrent NSAID or corticosteroid use
- Multiple bleeding risk factors 7, 8, 9
Important Caveats
While PPIs are safe with apixaban, be aware that:
PPIs reduce GI bleeding risk but do not eliminate it entirely—the benefit is most pronounced in high-risk patients 5, 7
The evidence shows associations rather than definitive causation, as most data comes from observational studies with potential confounding by indication 10, 4
Helicobacter pylori should be tested and treated in patients with history of peptic ulcer disease before starting anticoagulation 8
Under-prescription of PPIs is common in clinical practice—nearly 66% of high-risk warfarin patients who should receive PPIs do not 9, suggesting similar gaps likely exist for DOAC patients